Pfizer Inc. Company Profile
NYSE: PFEHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 9:43 AM ET
Pfizer at a glance
Pfizer Inc. (NYSE: PFE) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New York, NY. Pfizer is led by Dr. Albert Bourla D.V.M., Ph.D. and employs about 75,000 people. At a market capitalization of $156.74 billion, it is considered a large-cap company.
PFE is a member of the SP500. Its SEC Central Index Key (CIK) is 0000078003, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Pfizer do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Business description based on the company's public filings.
Company information
- Legal name
- Pfizer Inc.
- Ticker
- NYSE: PFE
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Albert Bourla D.V.M., Ph.D.
- Employees
- 75,000
- Headquarters
- 66 Hudson Boulevard East, New York, NY, United States
- Phone
- 212 733 2323
- Website
- pfizer.com
- Market cap
- $156.74B
- SEC CIK
- 0000078003
- Latest annual report
- 10-K · Feb 26, 2026
Index membership
Companies similar to Pfizer
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| NVONovo Nordisk A/S | 37.57 | -1.80% | $165.85B | vs PFE |
| ABTAbbott Laboratories | 98.42 | -0.30% | $170.30B | vs PFE |
| VRTXVertex Pharmaceuticals Incorporated | 500.72 | -0.97% | $126.91B | vs PFE |
| BMYBristol-Myers Squibb Company | 59.15 | -0.90% | $120.82B | vs PFE |
| SNYSanofi ADS | 40.01 | -0.49% | $95.86B | vs PFE |
| GSKGSK plc ADR | 46.50 | -1.11% | $93.15B | vs PFE |
| REGNRegeneron Pharmaceuticals Inc. | 731.56 | -1.42% | $75.32B | vs PFE |
| AZNAstraZeneca PLC | 158.87 | -0.79% | $246.39B | vs PFE |